In a subsequent study, dual targeting of EGFR and CDK4/6 by erlotinib and palbociclib, respectively, is additively effective in reducing tumor growth in TNBC xenografts and PDX cells expressing MMP17, EGFR, and RB, whereas PDX-TNBC cells without RB expression were resistant to this combination [428]. This evidence concerns the gene EGFR and neoplasm.